Relmada Therapeutics (RLMD) Misses Q4 EPS by 10c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.27), $0.10 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
• QSE closes $6M private placement with final tranche of $674K